Gruppi di Ricerca

Terapie innovative in Oncologia - Gruppo di Ricerca

REFERENTE - GROUP LEADER

Prof. PEDRAZZOLI Paolo

CURRICULUM VITAE REFERENTE

SPECIFIC ROLE

Coordination of the Unit's research activities.

GROUP MEMBERS
Agustoni F., Chiellino S., Corallo S., Galli G., Ferrari A. & OCTO Team, Ferraris E., Gandini C., Lasagna A., Monaco T. & nurses group, Pagani A., Rizzo G., Secondino S.

RESEARCH PROJECTS
- Clinical and translational studies in solid tumors (selection)
  - Phase I, II and III studies with new drugs and procedures in Lung Cancer stage III and IV, Breast Cancer, Mesothelioma and other solid tumors
  - Germ cell tumors: Role of miRNA in solid tumor (miRNA371 in germ cell cancer); autologous stem cell transplantation (prospective and retrospective studies)
  - Cell therapy in Nasopharyngeal Carcinoma and Colorectal cancer, stem cell transplantation
  - Immunotherapy including prediction of response
  - Alliance against Cancer (ACC): Gersom; and Lung Working groups / Radiomiomics studies in collaboration with Radiotherapy and Radiology Units
  - Preclinical studies in small bowel adenocarcinoma, colorectal Cancer, Breast Cancer
- Nutritional support in cancer patients, including drafting of national and international recommendations
  - Immunonutrition in head&neck cancer and lung cancer; artificial nutrition in gastric cancer
  - Assessment of nutritional risk and body composition in various oncological settings
  - Effects of amino-acid supplementation on lymphocytes, in patients with advanced gastrointestinal cancers
  - ACC Working Groups: Survivorship care and Nutrition Support in cancer patients
- Viral diseases and cancer, including drafting of national guidelines
  - Immunogenicity of anti-SARS-CoV-2 and HZ vaccines in cancer patients
  - Evaluation of T-cell response in patients with occult hepatitis B infection during immunotherapy
  - Evaluation of gut microbiota in breast cancer and in patients undergoing immunotherapy
  - Implications for Immunotherapy: Single-Cell profiling of liver-infiltrating immune cells of patients with NASH- and virus-related HCC.
5 BEST PAPERS
- Tagliamento M., Gennari A., Lambertini M., Salazar R., Harbeck N., Del Mastro L., Aguilar-Company J., Bower M., Sharkey R., Dalla Pria A., Plaja A., Jackson A., Handford J., Sita-Lumsden A., Martinez-Vila C., Matas M., Miguel Rodriguez A., Vincenzi B., Tonini G., Bertuzzi A., Brunet J., Pedrazzoli P., D'Avanzo F., Biello F., Sinclair A., Lee A.J.X., Rossi S., Rizzo G., Mirallas O., Pimentel I., Iglesias M., Sanchez de Torre A., Guida A., Berardi R., Zambelli A., Tondini C., Filetti M., Mazzoni F., Mukherjee U., Diamantis N., Parisi A., Aujayeb A., Prat A., Libertini M., Grisanti S., Rossi M., Zoratto F., Generali D., Saura C., Lyman G.H., Kuderer N.M., Pinato D.J., Cortellini A. Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer. Journal of Clinical Oncology, 2023;
- Pinto C., Zucali P.A., Pagano M., Grosso F., Pasello G., Garassino M.C., Tiseo M., Soto Parra H., Grossi F., Cappuzzo F., de Marinis F., Pedrazzoli P., Bonomi M., Gianoncelli L., Perrino M., Santoro A., Zanelli F., Bonelli C., Maconi A., Frega S., Gervasi E., Boni L., Ceresoli G.L. Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncology, 2021;
- Frittoli E., Palamidessi A., Iannelli F., Zanardi F., Villa S., Barzaghi L., Abdo H., Cancila V., Beznoussenko G.V., Della Chiara G., Pagani M., Malinverno C., Bhattacharya D., Pisati F., Yu W., Galimberti V., Bonizzi G., Martini E., Mironov A.A., Gioia U., Ascione F., Li Q., Havas K., Magni S., Lavagnino Z., Pennacchio F.A., Maiuri P., Caponi S., Mattarelli M., Martino S., d'Adda di Fagagna F., Rossi C., Lucioni M., Tancredi R., Pedrazzoli P., Vecchione A., Petrini C., Ferrari F., Lanzuolo C., Bertalot G., Nader G., Foiani M., Piel M., Cerbino R., Giavazzi F., Tripodo C., Scita G. Tissue fluidification promotes a cGAS-STING cytosolic DNA response in invasive breast cancer. Nature Materials, 2023;
- Pedrazzoli P., Lasagna A., Cassaniti I., Ferrari A., Bergami F., Silvestris N., Sapuppo E., Di Maio M., Cinieri S., Baldanti F. Vaccination for herpes zoster in patients with solid tumors: a position paper on the behalf of the Associazione Italiana di Oncologia Medica (AIOM). ESMO Open, 2022.
RUNNING FUNDS
- ACC, Ricerca Corrente San Matteo, Regione Lombardia, Grants/research supports as investigators in trials sponsored by Pharma Comp.
NATIONAL AND INTERNATIONAL STRATEGIC COLLABORATIONS
- UNIPV, ACC, AIOM, OECI, EBMT, ESMO, EORTC, SINPE, FAVO, CNAO, INT Milan, IGG.